We are live on ! Find out more
YMAB

Y-mAbs Therapeutics
YMAB

Delisted

YMAB was delisted on the 15th of September, 2025.

Back to rankings

100 hedge funds and large institutions have $303M invested in Y-mAbs Therapeutics in 2022 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 29 increasing their positions, 32 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

129% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 7

10% more funds holding

Funds holding: 91 → 100 (+9)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

9% less repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 32

2.75% less ownership

Funds ownership: 56.64% → 53.89% (-2.8%)

8% less capital invested

Capital invested by funds: $330M → $303M (-$26.8M)

Holders
100
Holders Change
+9
Holders Change %
+9.89%
% of All Funds
1.72%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
16
Increased
29
Reduced
32
Closed
7
Calls
$1.78M
Puts
–
Net Calls
+$1.78M
Net Calls Change
-$802K

Top Buyers

Rank Fund Capital Flow
1
DCM
Driehaus Capital Management
Illinois
+$4.92M
2
State Street
State Street
Massachusetts
+$2.91M
3
Citadel Advisors
Citadel Advisors
Florida
+$1.5M
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$1.29M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$1.23M

Top Sellers

Rank Fund Capital Flow
1
AllianceBernstein
AllianceBernstein
Tennessee
-$11M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$9.81M
3
PCH
Polar Capital Holdings
United Kingdom
-$6.97M
4
Morgan Stanley
Morgan Stanley
New York
-$1.97M
5
Invesco
Invesco
Georgia
-$1.63M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$41.8M -$1.31M -78,827 -3%
SI
2
Sofinnova Investments
California
$31.6M – – –
AllianceBernstein
3
AllianceBernstein
Tennessee
$31M -$11M -665,801 -24%
Wellington Management Group
4
Wellington Management Group
Massachusetts
$28.1M +$1.29M +78,090 +4%
Vanguard Group
5
Vanguard Group
Pennsylvania
$27.7M -$157K -9,495 -0.5%
State Street
6
State Street
Massachusetts
$27.7M +$2.91M +175,997 +10%
Fidelity Investments
7
Fidelity Investments
Massachusetts
$19.9M -$9.81M -592,385 -30%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$9.13M +$111K +6,727 +1%
MB
9
MPM BioImpact
Massachusetts
$6.4M – – –
Walleye Capital
10
Walleye Capital
New York
$6.31M +$351K +21,204 +5%
AG
11
Artal Group
Luxembourg
$5.77M – – –
Northern Trust
12
Northern Trust
Illinois
$4.75M -$67.5K -4,075 -1%
DCM
13
Driehaus Capital Management
Illinois
$4.29M +$4.92M +297,252 New
Morgan Stanley
14
Morgan Stanley
New York
$3.68M -$1.97M -118,664 -32%
Charles Schwab
15
Charles Schwab
California
$3.58M +$13.4K +807 +0.3%
PA
16
Perceptive Advisors
New York
$3.06M – – –
MSKCC
17
Memorial Sloan Kettering Cancer Center
New York
$2.76M – – –
Goldman Sachs
18
Goldman Sachs
New York
$2.64M +$519K +31,351 +21%
CS
19
Candriam SCA
Luxembourg
$2.49M – – –
LOAMS
20
Lombard Odier Asset Management (Switzerland)
Switzerland
$2.43M -$201K -12,138 -7%
CAM
21
Cormorant Asset Management
Massachusetts
$2.16M – – –
Dimensional Fund Advisors
22
Dimensional Fund Advisors
Texas
$1.91M -$1.45M -87,356 -40%
Renaissance Technologies
23
Renaissance Technologies
New York
$1.84M -$363K -21,900 -15%
D.E. Shaw & Co
24
D.E. Shaw & Co
New York
$1.67M +$1.23M +74,103 +179%
Bank of New York Mellon
25
Bank of New York Mellon
New York
$1.63M +$177K +10,698 +10%
1
2 3 4 5

YMAB Hedge Fund Activity: Q3 2022 in Review

100 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Y-mAbs Therapeutics (YMAB) for Q3 2022, worth a combined $303M — down 8.1% from $330M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new YMAB positions and 7 closed out — a net gain of 9 holders — while 29 added to existing stakes and 32 trimmed.

The largest buyer was Driehaus Capital Management, opening a new position worth an estimated $4.92M. The largest seller was AllianceBernstein, cutting an estimated $11M.

  • 100 institutional investors held Y-mAbs Therapeutics (YMAB) as of Q3 2022, up from 91 in Q2 2022.
  • Funds reported $303M of Y-mAbs Therapeutics stock for Q3 2022, down 8.1% quarter-over-quarter.
  • 16 funds opened new Y-mAbs Therapeutics positions in Q3 2022 and 7 closed out, a net change of +9 holders.
  • The largest Y-mAbs Therapeutics buyer in Q3 2022 was Driehaus Capital Management, an estimated $4.92M added.
  • The largest Y-mAbs Therapeutics seller in Q3 2022 was AllianceBernstein, an estimated $11M sold.

Based on aggregated 13F filings for Q3 2022.